作者：
Hasselgren, Catrin [1]
;
Bercu, Joel [2]
;
Cayley, Alex [3]
;
Cross, Kevin [4]
;
Glowienke, Susanne [5]
;
Kruhlak, Naomi [6]
;
Muster, Wolfgang [7]
;
Nicolette, John [8]
;
Reddy, M. Vijayaraj [9]
;
Saiakhov, Roustem [10]
;
Dobo, Krista [11]
作者单位：
Merck & Co Inc, West Point, PA 19486 USA
[1]
Genentech Inc, 1 DNA Way, San Francisco, CA 94080 USA
[2]
Novartis Pharma AG, Preclin Safety, CH-4057 Basel, Switzerland
[3]
Gilead Sci, 333 Lakeside Dr, Foster City, CA USA
[4]
US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD 20993 USA
[5]
AbbVie Inc, Preclin Safety, 1 North Waukegan Rd, N Chicago, IL USA
[6]
F Hoffmann Roche Ltd, Roche Innovat Ctr Basel, Pharmaceut Sci, Roche Pharmaceut Res & Early Dev
[7]
Multicase Inc, 23811 Chagrin Blvd,Suite 305, Beachwood, OH 44122 USA
[8]
Leadscope Inc, 1393 Dublin Rd, Columbus, OH 43215 USA
[9]
Pfizer Worldwide Res & Dev, 558 Eastern Point Rd, Groton, CT 06340 USA
[10]
Lhasa Ltd, Granary Wharf House,2 Canal Wharf, Leeds, W Yorkshire, England
[11]
发布时间
2021-04-22
换一批
